Sang‐We Kim

Overall Survival with Amivantamab–Lazertinib in <i>EGFR</i> -Mutated Advanced NSCLC

Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer

Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial

A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC

Repotrectinib in <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer

Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study

Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

Intracranial efficacy of sotorasib versus docetaxel in pretreated<i> KRAS</i> G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study